关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
" B) I! u! \7 Q/ s    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。

作者：来自澳大利亚
8 ~+ ?6 W, N. b$ F来源：Haematologica. 2011.8.9.
* Y( u2 Z4 `- t+ C3 {8 HDear Group,
8 L( }2 a7 t  i+ S: I; n
Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
therapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
' @3 u2 h* ]5 F. r: _remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
- O" y* J' v- Hdoes spike up the immune system so I hope more reports come out on this issue.
" k( b' m: e; s
The remarkable news about Sprycel cessation is that all 3 patients had failed
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
! F' ^8 F) ^+ p! E: r8 N5 Rdifferent from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.
+ n4 {0 f" p6 X& K. j
Hopefully, the doctors will report on a larger study and long-term to see if the
response off Sprycel is sustained.

' v2 {& K/ D' i0 ?/ s: \: K  |8 rBest Wishes,
. K4 h4 M  Q& vAnjana

1 d; w( x- O, X2 o- m( Z
5 S$ S( S2 L& B( K; t
Haematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
/ }! P; Y' x6 cSource
- E& L3 _) _0 X- s' x4 f# Q8 IAdelaide, Australia;

Abstract
Patients with chronic myeloid leukemia, treated with imatinib, who have a
durable complete molecular response might remain in CMR after stopping
5 L: m, e" g5 t- \6 Ctreatment. Previous reports of patients stopping treatment in complete molecular
; ?. T3 h; n8 Gresponse have included only patients with a good response to imatinib. We
3 B! O1 k$ C/ v& g1 odescribe three patients with stable complete molecular response on dasatinib
0 S' u* r& d: w3 Y, gtreatment following imatinib failure. Two of the three patients remain in
' ~" }) w6 \; g- Acomplete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
6 m) i' y  _; Z) O, cshow that the leukemic clone remains detectable, as we have previously shown in
" v+ Y0 w0 U) j+ ^1 d$ dimatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
/ O) ~- l) E' x" Awho relapsed and in one patient in remission. Our results suggest that the
; ~1 F8 Z: W% Q: H+ B% }7 mcharacteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
2 F8 f8 S8 _7 E, hdisease features.

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
& Q5 Q1 N2 F6 e3 N/ B5 j+ S2 k% l    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
+ K6 m2 z6 N8 Z7 I$ h' v
作者：来自法国STIM试验
! G' n9 z- {- j, S' ?8 F来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事